Aclaris Therapeutics meldet positive Ergebnisse aus Phase-1a-Studie zu ATI-052, einem neuartigen bispezifischen Antikörper.

Quelle: The Manila Times
Link: https://www.manilatimes.net/2026/04/28/tmt-newswire/globenewswire/aclaris-therapeutics-announces-positive-full-top-line-first-in-human-results-from-phase-1a-healthy-volunteer-clinical-trial-of-ati-052-a-novel-potential-first-in-class-anti-tslpil-4r-bispecific-antibody-and-announces-lichen-planus-as-lead-indication-for-ati-2138-an-oral-itkjak3-inhibitor/2330178